Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures

被引:12
作者
Boucher, S
Recordon-Pinson, P
Neau, D
Ragnaud, JM
Titier, K
Faure, M
Fleury, H
Masquelier, B
机构
[1] CHU Bordeaux, Hop Pellegrin, Dept Virol & Immunol Biol, F-33076 Bordeaux, France
[2] Hop Pellegrin, Dept Malad Infect, F-33076 Bordeaux, France
[3] Hop Pellegrin, Lab Pharmacol Clin, F-33076 Bordeaux, France
关键词
treatment interruption; virological failure; proviral DNA; HIV drug resistance;
D O I
10.1016/j.jcv.2005.01.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Treatment interruption (TI) in antiretroviral-treated patients on virological failure (VF) often results in a shift from resistant to wild-type HIV-1 in plasma. A clonal analysis was set out to determine the importance of archiving of resistant HIV-1 variants during TI and its relationship with the occurrence of a VF after treatment resumption. Methods: A fragment of the Pot gene was cloned and sequenced from peripheral blood mononuclear cells DNA sampled at the end of TI. Clonal sequences were compared to bulk plasma sequences determined before T1, after T1 and at VF. Results: Four patients were enrolled; all had a complete reversion to wild-type HIV-1 at the end of TI. In two patients with subsequent VF, archiving of minority resistant variants was detected in proviral DNA. Archived resistant variants were found to be phylogenetically linked to sequences detected before TI and at VF, suggesting the re-expansion of resistant HIV-1 from archived quasispecies. Conclusion: In patients having a TI in the context of VF, archiving of resistant HIV-1 variants in proviral DNA can be involved into the mechanisms of further VF after treatment resumption. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:288 / 294
页数:7
相关论文
共 15 条
[1]  
BENSON C, 2004, P 11 C RETR OPP INF
[2]   Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].
Deeks, SG ;
Wrin, T ;
Liegler, T ;
Hoh, R ;
Hayden, M ;
Barbour, JD ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK ;
Grant, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480
[3]   Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response [J].
Deeks, SG ;
Grant, RM ;
Wrin, T ;
Paxinos, EE ;
Liegler, T ;
Hoh, R ;
Martin, JN ;
Petropoulos, CJ .
AIDS, 2003, 17 (03) :361-370
[4]  
DELAUGERRE C, 2003, ANTIVIR THER, V8, pS163
[5]  
Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001
[6]  
GHOSN J, 2003, P 9 EUR AIDS C
[7]   Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen [J].
Izopet, J ;
Massip, P ;
Souyris, C ;
Sandres, K ;
Puissant, B ;
Obadia, M ;
Pasquier, C ;
Bonnet, E ;
Marchou, B ;
Puel, J .
AIDS, 2000, 14 (15) :2247-2255
[8]   Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following interruption and shift in resistance genotype [J].
Izopet, J ;
Souyris, C ;
Hance, A ;
Sandres-Sauné, K ;
Alvarez, M ;
Pasquier, C ;
Clavel, F ;
Puel, J ;
Massip, P .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (10) :1506-1510
[9]   Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097) [J].
Katlama, C ;
Dominguez, S ;
Gourlain, K ;
Duvivier, C ;
Delaugerre, C ;
Legrand, M ;
Tubiana, R ;
Reynes, J ;
Molina, JM ;
Peytavin, G ;
Calvez, V ;
Costagliola, D .
AIDS, 2004, 18 (02) :217-226
[10]  
KEARNEY M, 2003, ANTIVIR THER, V3, pS96